Marshall Wace LLP Invests $433,000 in Pro-Dex, Inc. (NASDAQ:PDEX)

Marshall Wace LLP bought a new position in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 9,260 shares of the medical instruments supplier's stock, valued at approximately $433,000. Marshall Wace LLP owned approximately 0.28% of Pro-Dex as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Ritholtz Wealth Management bought a new position in shares of Pro-Dex during the 4th quarter worth about $572,000. American Century Companies Inc. bought a new stake in shares of Pro-Dex in the 4th quarter worth about $558,000. Russell Investments Group Ltd. acquired a new stake in shares of Pro-Dex during the fourth quarter worth approximately $327,000. Geode Capital Management LLC raised its stake in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock valued at $819,000 after acquiring an additional 2,296 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Pro-Dex during the 4th quarter valued at $202,000. 15.28% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Raymond E. Cabillot sold 5,151 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $50.00, for a total value of $257,550.00. Following the completion of the sale, the director now directly owns 300,695 shares of the company's stock, valued at $15,034,750. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 21,383 shares of company stock valued at $1,031,182 in the last quarter. Company insiders own 47.50% of the company's stock.

Pro-Dex Stock Up 1.0 %

PDEX traded up $0.45 during trading on Friday, reaching $43.83. The company had a trading volume of 11,886 shares, compared to its average volume of 28,419. The company has a market cap of $142.93 million, a P/E ratio of 21.81 and a beta of 0.37. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. Pro-Dex, Inc. has a 12 month low of $16.84 and a 12 month high of $70.26. The business's fifty day moving average price is $52.92 and its 200 day moving average price is $46.07.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.98 EPS for the quarter, topping the consensus estimate of $0.47 by $0.51. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. The business had revenue of $17.41 million during the quarter, compared to analysts' expectations of $17.70 million. Equities analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Pro-Dex from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th.

Pro-Dex Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.